In melanoma models with T cell dysfunction, PSGL-1 deficiency leads to programmed cell death-1 (PD-1) downregulation, an improved T cell response, and tumor control, and PSGL-1 acts as a negative regulator of CD4+ T cells in a variety of diseases, including cancer. This evidence concerns the gene CD4 and cancer.